#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Methylmalonic acidaemia Short stature Haemophilia A with anti factor VIII Pancreatic carcinoma metastatic Eosinophilic oesophagitis Turner's syndrome Henoch-Schonlein purpura Marginal zone lymphoma recurrent Biliary neoplasm Carcinoid tumour Primary amyloidosis Acquired C1 inhibitor deficiency Pulmonary hypertension Congenital growth hormone deficiency Burkitt's lymphoma refractory More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy – Treatment Pleural mesothelioma malignant – Treatment Idiopathic pulmonary fibrosis – Trials in Disease Erdheim-Chester disease – Life with Disease Pemphigus Chondrosarcoma metastatic – Life with Disease Atypical haemolytic uraemic syndrome – Diagnostics Haemophilia A without inhibitors Sarcoidosis – Life with Disease Lysosomal storage disorder – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Camonsertib Methoxyflurane Ibuprofen Sodium Dihydrate Inotuzumab Ozogamicin Efepoetin Alfa 1,3-BUTYLENE GLYCOL Nizaracianine Triflutate Lepidoglyphus Destructor Clobetasol Mk-4830 Bimekizumab Fingolimod Hydrochloride Orismilast Cemiplimab Mps-112 Atuliflapon GSKVX000000030825 Fremanezumab Daxdilimab Rbd5044 Sodium More therapies…

    Learn about Your Condition

    Pseudomyxoma peritonei SAPHO syndrome Apheresis Schizophrenia Yellow fever Anxiety disorder Rabies Richter's syndrome Peptostreptococcus infection Adenomyosis Lichen planopilaris Relapsing multiple sclerosis Postoperative wound infection Endometrial cancer stage IV Onychomycosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Haga Hospital

Haga Hospital

Els Borst-Eilersplein 275, Hague, 2545 AA, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Capivasertib
    • Abiraterone Acetate
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Deutivacaftor
    • Tezacaftor
    • Vanzacaftor
    Austria Belgium Czechia Denmark France Germany +10

  • Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    • Venetoclax
    Belgium Denmark Finland The Netherlands Norway Sweden

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14

  • Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • Pembrolizumab
    Bulgaria Czechia Finland France Germany Greece +8

  • Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    Belgium Czechia Denmark France Germany Greece +7

  • Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Belgium Ireland Italy The Netherlands Portugal Spain

  • Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Stage II and III Colon Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colon cancer stage II
    • Colon cancer stage III
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Placebo
    The Netherlands

  • Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing Multiple Sclerosis Starting Anti-CD20 Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    The Netherlands

  • Study on Reducing Bleeding by Omitting Aspirin in Patients with Non-ST Elevation Acute Coronary Syndrome

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute coronary syndrome
    Investigated Drugs:
    • Acetylsalicylic Acid
    Belgium The Netherlands
Previous Page
1 … 10 11 12 13 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!